Cowdy Philip G. 4/A

What Happened Philip G. Cowdy, a director of Bioventus, was reported in an amended Form 4 as the recipient of a grant of 2,700 restricted stock units (RSUs) dated April 1, 2021. The reported acquisition price was $0.00 (award/derivative), but the company says the grant was not accepted by Mr. Cowdy and, as of April 1, 2021, he held no derivative or non-derivative securities of the issuer. This filing amends an inadvertent Form 4 originally submitted on April 5, 2021.

Key Details

• Transaction type: Award/Grant (code A) of 2,700 RSUs dated 2021-04-01, reported at $0.00 per share (derivative).
• Shares owned after transaction: The filer held no derivative or non-derivative securities as of 2021-04-01.
• Footnotes: F1 states the April 5, 2021 Form 4 mistakenly reported an award that was not accepted; F2 = None.
• Filing status: This is an amended Form 4 filed April 14, 2026 correcting the earlier inadvertent report (appears to be a late amendment).

Context Restricted stock units are awards that convert into shares upon vesting; because Mr. Cowdy did not accept the award, there is no change in his ownership and no economic stake implied by this filing. For retail investors, corrected or withdrawn award reports like this do not indicate insider buying or selling intent.